General description
INN
Cabergoline
Medicine type
Chemical agent
EML status history
Application rejected in 2015
(TRS
994)
for
Parkinson disease
Added in 2023
(TRS
1049)
for
Other specified benign neoplasm of endocrine glands
Wikipedia
DrugBank
Recommendations
Section
Antiseizure medicines
- Oral > Solid: 0.5 mg
Indications
Section
Medicines for disorders of the pituitary hormone system
- Oral > Solid > tablet: 0.5 mg; 1 mg